Graves’ disease: an uncommon cause of late sequelae following DRESS (drug reaction with eosinophilia and systemic symptoms)

A 14-year-old Thai boy with history of bilateral vesicoureteral reflux diagnosed at the age of 1 year. Then, he progressed to chronic kidney disease and secondary hypertension, respectively at his 6 years of age. Routine medication was enalapril (0.5 mg), (2-tab oral twice a day). He was prescribed allopurinol (100 mg), (1-tab oral once daily) after the diagnosis and persistent of hyperuricemia 13.2 (3.5–7.2 mg/dL) at almost 14-year-old. Forty-five days later, he developed fever and erythematous rash which started on both legs and progressed to entire body within 6 days. There was no other over the counter and routine medication. Allopurinol was discontinued after the rash appeared.

Physical examination showed centrofacial edema, small vesiculopustular rash on patient’s face and neck and erythematous confluent maculopapular rash on trunk and extremities. There was no conjunctival injection or mucosal involvement. Left cervical lymph nodes were palpable, size 1.5 cm×2 nodes. Laboratory revealed hemoglobin 13.5 g/dL, WBC 11,500/mm^3, eosinophil 5% (absolute eosinophil count 576), and elevated aspartate aminotransferase, 136 U/L, alanine transaminase, 239 U/L. Drug reaction with eosinophilia and systemic symptoms (DRESS) was diagnosed from allopurinol as the suspected culprit drug by the Registry of Severe Cutaneous Adverse Reactions (RegiSCAR) criteria, including fever, lymph node enlargement, transaminitis, and eosinophilia. He received pulsed intravenous methylprednisolone (1 g/day: 30 mg/kg/day, equal to prednisolone 800 mg) for 6 days, then oral prednisolone 60 mg initially with tapering until 20 mg daily in 4 weeks. HLA B^*58:01 was positive. The liver enzymes gradually returned to normal range within 6 weeks and the rash became less edematous, yet more hyperpigmentation.

Two months later, he developed erythroderma with progressive confluent erythematous maculopapular eruption. Relapsed DRESS was suspected. So, he received an increased oral prednisolone to 60 mg daily with gradual tapering by 5 mg/wk until 40 mg daily. He then had a 2-week history of dyspnea and tremor on his hands, with a sudden onset of fever for 1 day prior to the second admission. Physical examination revealed body temperature 37ºC, heart rate 160/min, SpO₂ 94%, subcostal retraction with fine crepititation on both lower lung zones. Chest x-ray revealed bilateral ground glass opacity.

During PICU stay, he had persistent tachycardia (135–155/min) with fine tremor. Thyroid function test yielded TSH (<0.0083 uIU/mL), free thyroxine (FT4) (2.14 ng/dL; 0.8–2.0), and free triiodothyronine (FT3) (3.05 pg/mL; 2.9–5.6). Thyroid storm was diagnosed with total Burch-Wartofsky Point score of 45. He was prescribed hydrocortisone (100 mg IV q 8 hours: 300 mg/day), methimazole (5 mg), (5-tab oral OD, 0.3 mg/kg/day), and propranolol (40 mg), (1-tab oral q 6 hours, 0.8 mg/kg/dose).

The evaluation of hyperthyroidism revealed positive antithyroid antibody.

Table 1. Test results of this patient at baseline, upon the DRESS diagnosis, and upon the Graves’ disease diagnosis

| Laboratory          | At baseline | DRESS diagnosis | Graves’s disease diagnosis |
|---------------------|-------------|-----------------|---------------------------|
| BUN (mg/dL)         | 26 (7–20)   |                 | Hb 13.5 g/dL, WBC 15,660/mm³, Eo 1%, Eosinophil count 157 | Hb 13.9 g/dL, WBC 16,610/mm³, Eo 0.7%, Eosinophil count 116 |
| Cr (mg/dL)          | 1.37 (0.7–1.2) |                 | AST 136, ALT 239 HLA B^* 58:01 |AST 16, ALT 43 |
| Uric acid (mg/dL)   | 13.2 (3.5–7.2) |                 | -                          | - |
| Electrolyte (mmol/L)| Na 139, K 4.8, Cl 105, HCO₃ 23 |                 | -                          | - |
| Total calcium (mg/dL) | 10.1 (8.5–10.5) |                 | -                          | - |
| Phosphate (mg/dL)   | 5.1 (2.3–4.7) |                 | -                          | - |
| CBC                 | Hb 13.2 g/dL, WBC 15,660/mm³, Eo 1%, Eosinophil count 157 |                 | Hb 13.5 g/dL, WBC 11,500/mm³, Eo 5%, Eosinophil count 576 | - |
| AST, ALT (IU/L)     | AST 14, ALT 46 |                 | AST 136, ALT 239 HLA B^* 58:01 |AST 16, ALT 43 |
| HLA                 | -           |                 | -                          | - |
| Thyroid function test | TSH <0.0083 uIU/mL, FT4 2.14 ng/dL (0.8–2.0) FT3 3.05 pg/mL (2.9–5.6) | - | - |
| Thyroid autoantibodies | Anti-TSHR 17 IU/mL (0–1.75) Anti-T 371 IU/mL (<115) Anti-TPO 36.6 IU/mL (<36) | - | - |
| Autoimmune type I Diabetes mellitus | Negative | CMV: positive HHV-6, -7: negative EBV: negative | - | - |
| Viral panel by DNA Microarray | CMV: positive | HHV-6, -7: negative EBV: negative | - | - |

DRESS, drug reaction with eosinophilia and systemic symptoms; BUN, blood urea nitrogen; Cr, creatinine; CBC, ; Hb, hemoglobin; WBC, white blood cell; AST, aspartate transaminase; ALT, alanine transaminase; Anti-T, thyroid globulin antibody; Anti-TPO, thyroid peroxidase antibody; Anti-TSHR, TSH receptor antibody; TSH, thyroid stimulation hormone; CMV, cytomegalovirus; HHV, human herpesvirus; EBV, Epstein-Barr virus; FT3, free triiodothyronine; FT4, free thyroxine.

Received: 4 March 2022, Revised: 25 May 2022, Accepted: 2 June 2022

This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Copyright © 2022 by The Korean Pediatric Society
stimulating hormone receptor (anti-TSHR) of 17 IU/L (0–1.75), antithyroglobulin antibody (anti-T) of 371 IU/mL (<115), and antithyroxyne peroxidase antibody (anti-TPO) of 36.6 IU/mL (<34), which suspected of having Graves’ disease. The summation for the test result of this patient was shown in Table 1.

After a 5-day course of hydrocortisone (300 mg/day) for thyroid storm treatment, prednisolone was restarted at 60 mg daily with tapering by 5 mg every 2 weeks. Subsequent thyroid function test 3 weeks later showed FT4 0.58 (0.7–1.48 ng/dL), FT3<1.50 (1.6–4.0 pg/mL) and TSH<0.0083 (0.35–7.94 uIU/mL). Methimazole was discontinued due to the possibility of over suppression.

Incidence and clinical manifestation of DRESS

The estimated risk of DRESS syndrome is about 1:1,000 and 1:10,000.1,2) The causative agents include anticonvulsants, antimicrobial, antiviral, allopurinol, antihypertensive, antidepressant, and nonsteroidal anti-inflammatory drugs (NSAIDs).3)

The presumptive pathophysiologic mechanisms of DRESS are complexity. CD4+, CD8+, Tregs, and mononuclear cells are involved in DRESS drug-specific T cells, plasmacytoid dendritic cells, and monocytes. Dermal dendritic cells could produce chemokine, such as CCL17/TARC, which could potentially attract Th2 cells, and monocytes. Dermal dendritic cells could produce chemoattractant for the test result of this patient was shown in Table 1.

After a 5-day course of hydrocortisone (300 mg/day) for thyroid storm treatment, prednisolone was restarted at 60 mg daily with tapering by 5 mg every 2 weeks. Subsequent thyroid function test 3 weeks later showed FT4 0.58 (0.7–1.48 ng/dL), FT3<1.50 (1.6–4.0 pg/mL) and TSH<0.0083 (0.35–7.94 uIU/mL). Methimazole was discontinued due to the possibility of over suppression.

Table 2. Cases of DRESS with Graves’ disease in the literature

| Reference | Age (yr)/sex | Culprit drug | Symptoms of Graves’ disease | Onset after diagnosis DRESS | Thyroid function test | Thyroidautoantibodies, others | Treatment | Co-occurrence autoimmune conditions |
|-----------|-------------|--------------|-----------------------------|----------------------------|----------------------|-----------------------------|-----------|----------------------------------|
| Chen et al.2) | 27/M | Ampicillin | Palpitation, Hand tremor | 1.2 Month (36 days) | Primary hyperthyroidism: FT4=3.7 ng/dL (0.6–1.75) TSH=0.056 µIU/mL (0.1–4.5) | Anti-T: positive | Carbimazole | Alopecia |
| | | | | | | TSH binding inhibitory immunoglobulin concentration: elevated |
| Chen et al.3) | 33/F | Carbamazepine | Palpitation, Insomnia, Weight loss, Blurred vision, Exophtalmos | 8.7 Months | Primary hyperthyroidism: FT4=4.8 mg/dL (0.6–1.75) TSH=0.008 µIU/mL (0.1–4.5) | Echogram: autoimmune thyroid disorder | Carbimazole | Propranolol | Alopecia |
| | | | | | | | | | |
| Descamps | 31/M | Minocycline | N/A | 5 Months (2 months after stop-steroid) | Hyperthyroidism | Anti-TSHR: positive | N/A | Interstitial renal insufficiency |
| | | | | | | | | | |
| Shiiya et al.4) | 46/M | Carbamazepine | N/A | 12.2 Months | N/A | Anti-T: positive | Anti-TPO: positive | N/A | N/A |
| | | | | | | | | | |
| Shiiya et al.4) | 38/F | Sulfamethoxazole | N/A | 19.7 Months | N/A | Anti-T: positive | Anti-TPO: positive | N/A | N/A |
| | | | | | | | | | |
| Shiiya et al.4) | 42/F | Zonisamide | N/A | 26 Months | N/A | N/A | Anti-T: positive | Anti-TPO: positive | N/A |
| | | | | | | | | | |
| Brown et al.4) | 15/F | Minocycline | No symptom | 1.7 Months (51 days) | Thyroid function test: primary hyperthyroidism: T3=452 ng/dL (60–181) FT4=4.9 ng/dL (1.1–1.8) | Anti-T: positive | Anti-TPO: positive | N/A | Type 1 DM (7 months) |
| | | | | | | | | | |
| | | | | | | | | | |
| | | | | | | | | | |
| | | | | | | | | | |
| | | | | | | | | | |

DRESS, drug reaction with eosinophilia and systemic symptoms; FT4, free thyroxine; TSH, thyroid-stimulating hormone; N/A, not available; Anti-TSHR, TSH receptor antibody; Anti-T, thyroglobulin antibody; Anti-TPO, thyroid peroxidase antibody; HHV, human herpesvirus; DM, diabetes mellitus; TSI, thyroid-stimulating immunoglobulin; FT3, free triiodothyronine.

IL-5, IL-4, and IL-13 are produced by Th2 T cells, innate type 2 lymphocytes, and CD4+ T cells, respectively. The function of IL-5 is eosinophil-specific differentiation to develop eosinophilia.3)

Our patient had multiple risk factors, such as time-related factors about 6 weeks after commencing, genetic factors of HLAB*58:01, and drug-concentration factors of initial dose 100 mg, and chronic kidney disease.2,4

Dermatologic manifestations are variable, including diffuse pruritic macular, erythroderma, polymorphous eruption, and exfoliative dermatitis. Morbilliform rash is the most common presentation.3) Edema of the face and periorbital area is also reported in approximately 25% of the cases.5)

Liver is the most frequently involved internal organ, followed by hematologic, lymphatic system, renal, pulmonary, and cardiac involvements.1)
bility and environmental factors, such as viral infection, potentially is likely to cause immune dysregulation.7 Multiple and complex mechanisms are proposed for pleiotropic cytokines releasing, while alteration of cytokines after DRESS could affect the absence or development of autoimmune thyroid disease.7

There are diversities of thyroid dysfunction onset after DRESS syndrome diagnosis, ranging from 0–36 months in the adult patients.6 Drug-induced thyroid dysfunction possibly develops up to 53 months after the diagnostic onset.8

The patients who develop Graves’ disease similar to our patient after DRESS diagnosis in the English literature were summarized in Table 2.7(9-11) The majority of culprit drugs were antibiotics. The onset of Graves’ disease was 1.2–26 months (median, 8.7 months). The minority of these patients had clinical symptoms of hyperthyroidism and co-occurrence autoimmune conditions.

**Patient outcome**

In our case, the patient clinically had hyperthyroidism combined with slightly high FT4 and low TSH at 4 months after DRESS diagnosis with positive antithyroid antibodies. Methimazole and propranolol was prescribed, and he was rapidly recovered within 3 weeks. However, a thyroid function test should be followed and closely monitored for several years.

In conclusion, the screening and monitoring of thyroid dysfunction and autoimmune conditions should be strongly recommended for several months after the onset of DRESS symptom.

Therdpong Tempark, MD1, Amatanun Tangthanapalakul, MD2, Tawatchai Deekajorndech, MD3, Susheera Chatproedprai, MD3, Vichit Supornsilchai, MD3, Siriwan Wananukul, MD1

1Division of Dermatology, Department of Pediatrics, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand; 2Department of Pediatrics, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand; 3Division of Nephrology, Department of Pediatrics, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand; 4Division of Endocrinology, Department of Pediatrics, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand

Corresponding author: Therdpong Tempark, MD Department of Pediatrics, 11th Floor, Sor Kor Building, Rama IV Rd., Pathumwan, Bangkok 10330, Thailand
Email: therdpnhu@yahoo.com
https://orcid.org/0000-0001-5645-2135

**Footnotes**

Conflicts of interest: No potential conflict of interest relevant to this article was reported.

Funding: This study received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

Acknowledgment: The authors would like to thank Ms. Sunatee Kessung for her assistance in editing and revising this manuscript.

Author contribution:
Conceptualization: TT, AT; Data curation: TT, AT; Formal analysis: TT; Funding acquisition: TT; Methodology: TT, AT; Project administration: TT; Visualization: TT, AT, TD, SC, VS, SW; Writing - original draft: TT, AT; Writing - review & editing: TT, AT, TD, SC, VS, SW

**References**

1. Husain Z, Reddy BY, Schwartz RA. DRESS syndrome: Part I. Clinical perspectives. J Am Acad Dermatol 2013;68:693.e1-14.
2. Tempark T, John S, Rerknimitr R, Satapornpong P, Sukasem C. Drug-induced severe cutaneous adverse reactions: insights into clinical presentation, immunopathogenesis, diagnostic methods, treatment, and pharmacogenomics. Front Pharmacol 2022;13:832048
3. Yang D, Han Z, Oppenheim JJ. Alarmins and immunity. Immunol Rev 2017:280:41-56.
4. Stamp LK, Barclay ML. How to prevent allopurinol hypersensitivity reactions? Rheumatol Oxf. 2018;57:i35-41.
5. Ang CC, Wang YS, Yousuff EL, Tay YK. Retrospective analysis of drug-induced hypersensitivity syndrome: a study of 27 patients. J Am Acad Dermatol 2010;63:219-27.
6. Tempark T, Deekajorndech T, Chatproedprai S, Supornsilchai V, Wananukul S. Late sequelae of drug reaction with eosinophilia and systemic symptoms (DRESS) cause thyroid dysfunction and thyroiditis: review of literature. J Pediatr Endocrinol Metab 2022;35:567-75.
7. Chen YC, Chang CY, Cho YT, Chiu HC, Chu CY. Long-term sequelae of drug reaction with eosinophilia and systemic symptoms: a retrospective cohort study from Taiwan. J Am Acad Dermatol 2013;68:459-65.
8. Deng M, Wu H, Yu M, Tian Y, Li Y, Xiao X. Co-occurrence of multiple endocrine abnormalities induced by the DIHS/DRESS. Int J Endocrinol 2019;2019:7959615.
9. Descamps V. Drug reaction with eosinophilia and systemic symptoms (DRESS) cause thyroid dysfunction and thyroiditis: human herpesvirus-6, the possible common link. Br J Dermatol 2013;169:952.
10. Shiya C, Ouchi T, Funakoshi T, Amagai M, Takahashi H. Autoimmune and inflammatory diseases occur in cases of drug-induced hypersensitivity syndrome but not in suspected cases. J Dermatol 2021;48:e45-6.
11. Brown RJ, Rother KL, Arman H, Mercurio MG, Wang R, Looney RJ, et al. Minocycline-induced drug hypersensitivity syndrome followed by multiple autoimmune sequelae. Arch Dermatol 2009;145:63-6.

**How to cite this article:** Tempark T, Tangthanapalakul A, Deekajorndech T, Chatproedprai S, Supornsilchai V, Wananukul S. Graves’ disease: an uncommon cause of late sequelae following DRESS (drug reaction with eosinophilia and systemic symptoms). Clin Exp Pediatr 2022;65:602-4. https://doi.org/10.3345/cep.2022.00381